Duration of radioprotective effects of antithyroid drug therapy is still not clear
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1819477 | PMC |
| http://dx.doi.org/10.1136/bmj.39140.373646.BE | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the promising therapeutic benefits of iodine and radioiodine in breast cancer cell lines.
Narra J
December 2024
Department of Physiology, Faculty of Medicine, Universitas Andalas, Padang, Indonesia.
Iodine has an anti-proliferative effect on cancer cells; however, its effects have not been explored adequately. The aim of this study was to evaluate the therapeutic potential of iodine and radioiodine by assessing their effects on the viability of various breast cancer cell lines: MCF7, SKBR3, and MDA-MB231. The viability of cells was measured in treated cells exposed to six doses of iodine (5, 10, 20, 40, 60, 80 µM) and two doses of radioiodine (3.
View Article and Find Full Text PDFDe novo thyroid eye disease following COVID vaccination several years after radioiodine therapy.
JRSM Open
January 2025
Department of Endocrinology, Diabetes and General (Internal) Medicine, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent ST4 6QG, UK.
The delayed onset of thyroid eye disease is well recognised but less commonly perceived in routine clinical practice and this case report serves as a reminder for a high index of suspicion in at-risk patients.
View Article and Find Full Text PDFINFLUENCE OF RADIOIODINE THERAPY ON ORAL HEALTH AND SALIVARY PRODUCTION IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA.
Endocr Pract
January 2025
Endocrinology Division, Department of Internal Medicine, School of Medical Sciences, University of Campinas, São Paulo, Brazil. Electronic address:
Objectives: To evaluate the characteristics related to oral health and salivary production in patients with Differentiated Thyroid Carcinoma (DTC) after radioiodine therapy (RIT).
Methods: Cross-sectional study, which included patients with DTC after ablative and/or adjuvant RIT. Patients underwent assessment of oral health conditions, subjective assessment of xerostomia and measurement of salivary flow.
The Interplay Between High Cumulative Doses of Radioactive Iodine and Type 2 Diabetes Mellitus: A Complex Cardiovascular Challenge.
Int J Mol Sci
December 2024
Nuclear Medicine Department, University of Medicine and Pharmacy "Carol Davila" Bucharest, 050474 Bucharest, Romania.
Starting from the metabolic profile of type 2 diabetes mellitus (T2DM), we hypothesized that the mechanisms of ¹³¹I-induced cardiotoxicity differ between patients diagnosed with differentiated thyroid cancer (DTC) with/without T2DM, with metformin potentially acting as a cardioprotective agent by mitigating inflammation in patients with T2DM. To address this hypothesis, we quantified, using ELISA, the serum concentration of several key biomarkers that reflect cardiac injury (NT-proBNP, NT-proANP, ST2/IL-33R, and cTn I) in 74 female patients with DTC/-T2DM and 25 with DTC/+T2DM treated with metformin. All patients received a cumulative oral dose of I exceeding 150 mCi (5.
View Article and Find Full Text PDFPleural metastases from differentiated thyroid cancer: clinical features and long-term outcomes.
Eur Thyroid J
January 2025
Z Qiu, Department of Nuclear Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Shanghai, 200233, China.
Objective: Pleural metastasis (PM) is rare in patients with differentiated thyroid cancer (DTC). Radioiodine (131I) therapy has been the main treatment for postoperative metastasis and recurrence of DTC. However, clinical data on PM from DTC are limited.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!